3rd Quarter - Report
THE MCMANUS GROUP for AMGEN
Firm
Client
Income
$50,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Access and reimbursement for Part B and Part D drugs. Advocating for access to biosimilars. Provisions related to vial wastage rebates in Medicare Part B including in Sec. 102 of S.2164/H.R. 19 - Lower Costs, More Cures Act of 2021 and Sec. 90004 of H.R. 3684 - Infrastructure Investment and Jobs Act. Provisions included in Subtitle J of H.R. 5376 - Build Back Better Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
| ALANNA TEMME | LD, Rep. Jon Porter |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.